R W Price

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    J Neurovirol 10:44-51. 2004
  2. ncbi request reprint Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment
    Asa Mellgren
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Antivir Ther 10:701-7. 2005
  3. pmc Antiretroviral therapy and central nervous system HIV type 1 infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94117, USA
    J Infect Dis 197:S294-306. 2008
  4. pmc Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin
    Richard W Price
    Department of Neurology, University of California, San Francisco, CA, USA
    Antivir Ther 13:369-74. 2008
  5. pmc Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, Bldg 1 Room 101, Potrero Avenue, Box 0870 1001, San Francisco, CA, 94110, USA
    J Neuroimmune Pharmacol 8:1147-58. 2013
  6. pmc Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
    Aylin Yilmaz
    Department of Infectious Diseases, University of Gothenburg, Journalvagen 10, Gothenburg, 416 50, Sweden
    J Neuroinflammation 10:62. 2013
  7. doi request reprint Targeting chronic central nervous system HIV infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, San Francisco, CA, USA
    Antivir Ther 17:1227-31. 2012
  8. pmc The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
    Thomas E Angel
    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
    Clin Proteomics 9:3. 2012
  9. pmc Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
    Magnus Gisslen
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
    BMC Neurol 9:63. 2009
  10. pmc The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?
    Magnus Gisslen
    Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg, Sweden
    BMC Infect Dis 11:356. 2011

Research Grants

  1. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2004
  2. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2004
  3. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2004
  4. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2005
  5. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2006
  6. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2006
  7. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2007
  8. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2009
  9. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2003
  10. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2003

Detail Information

Publications45

  1. ncbi request reprint Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    J Neurovirol 10:44-51. 2004
    ..The proportionally greater increase in CSF HIV after treatment interruption indicates that CSF HIV infection is often more effectively suppressed by combination antiretroviral therapy than is systemic infection...
  2. ncbi request reprint Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment
    Asa Mellgren
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Antivir Ther 10:701-7. 2005
    ..We conclude that the central nervous system (CNS) is usually not a 'sanctuary site', difficult to reach with combination antiretroviral treatment...
  3. pmc Antiretroviral therapy and central nervous system HIV type 1 infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94117, USA
    J Infect Dis 197:S294-306. 2008
    ..With better control of these severe disorders, attention has turned to the possible consequences of chronic silent infection and the issue of whether indolent, low-grade brain injury might require earlier treatment intervention...
  4. pmc Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin
    Richard W Price
    Department of Neurology, University of California, San Francisco, CA, USA
    Antivir Ther 13:369-74. 2008
    ..Here, we define cerebrospinal fluid (CSF) enfuvirtide pharmacokinetics and present a case illustrating the use of enfuvirtide as a probe to trace the origins of CSF HIV-1 quasispecies...
  5. pmc Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, Bldg 1 Room 101, Potrero Avenue, Box 0870 1001, San Francisco, CA, 94110, USA
    J Neuroimmune Pharmacol 8:1147-58. 2013
    ..Both hypothesis-based and discovery methods can be useful in advancing the definition and use of these biomarkers. ..
  6. pmc Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
    Aylin Yilmaz
    Department of Infectious Diseases, University of Gothenburg, Journalvagen 10, Gothenburg, 416 50, Sweden
    J Neuroinflammation 10:62. 2013
    ..We studied decay characteristics of neopterin in CSF and blood after commencement of ART in HIV-infected subjects and estimated the set-point levels of CSF neopterin after ART-mediated viral suppression...
  7. doi request reprint Targeting chronic central nervous system HIV infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, San Francisco, CA, USA
    Antivir Ther 17:1227-31. 2012
    ..Although there are important questions regarding the theoretical underpinnings of both this score and its application, the findings present a novel slant on therapy...
  8. pmc The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
    Thomas E Angel
    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
    Clin Proteomics 9:3. 2012
    ..abstract:..
  9. pmc Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
    Magnus Gisslen
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
    BMC Neurol 9:63. 2009
    ..Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients...
  10. pmc The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?
    Magnus Gisslen
    Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg, Sweden
    BMC Infect Dis 11:356. 2011
    ..This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI)...
  11. pmc Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
    Serena S Spudich
    Department of Neurology, University of California, San Francisco, USA
    BMC Infect Dis 5:98. 2005
    ..Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful window into and model of human CNS HIV infection...
  12. pmc Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
    Lars Hagberg
    Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg SE 41685 Sweden
    AIDS Res Ther 7:15. 2010
    ....
  13. pmc Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study
    J C Probasco
    Department of Neurology, University of California San Francisco, CA, USA
    Neurology 71:521-4. 2008
    ..Based on the potential immunomodulatory and antiviral properties of HMG-CoA reductase inhibitors (statins), we examined the effect of atorvastatin on CSF HIV-1 infection and associated CSF abnormalities in a small pilot study...
  14. pmc Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study
    Emily L Ho
    Department of Neurology1 University of California San Francisco, San Francisco, CA, USA
    AIDS Res Ther 8:17. 2011
    ..abstract:..
  15. ncbi request reprint Biomarkers of HIV-1 CNS infection and injury
    R W Price
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 69:1781-8. 2007
    ..This review considers the rationale and prospects of these approaches...
  16. pmc Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
    Elizabeth Sinclair
    Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 47:544-52. 2008
    ..To define the effect of antiretroviral therapy (ART) on activation of T cells in cerebrospinal fluid (CSF) and blood, and interactions of this activation with CSF HIV-1 RNA concentrations...
  17. ncbi request reprint CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy
    Marta Valle
    Department of Biopharmaceutical Sciences, University of California San Francisco, USA
    Brain 127:1047-60. 2004
    ..The time course of therapy-induced changes links CSF QUIN to local infection and supports the action of antiviral therapy in ameliorating immunopathological brain injury and ADC...
  18. ncbi request reprint Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection
    Barbara L Shacklett
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California, USA
    J Infect Dis 189:2202-12. 2004
    ..The central nervous system (CNS) is a recognized target for human immunodeficiency virus type 1 (HIV-1). CD8(+) T cells may mediate viral clearance from the CNS but also may contribute to immune-mediated neuronal damage...
  19. ncbi request reprint Cerebrospinal fluid response to structured treatment interruption after virological failure
    R W Price
    Department of Neurology, University of California San Francisco and San Francisco General Hospital, 94110 3518, USA
    AIDS 15:1251-9. 2001
    ..We report initial observations of cerebrospinal fluid (CSF) HIV-1 infection in five patients undergoing serial lumbar punctures (LPs) during STI undertaken following virological failure...
  20. ncbi request reprint Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 194:926-30. 2006
    ..CCR5 inhibitors may thus be best strategically used before salvage therapy and before significant CD4 + T cell depletion...
  21. ncbi request reprint Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy
    Jutta K Neuenburg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94158, USA
    AIDS 19:1351-9. 2005
    ..Although clinical brain disease is uncommon during combination antiretroviral therapy (ART), autopsy series indicate that HIV-infected brain tissue can contain high numbers of monocytes/macrophages despite ART...
  22. ncbi request reprint HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia
    Serena S Spudich
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    J Infect Dis 191:890-8. 2005
    ..Using an in vitro functional entry assay, we examined utilization of 2 principal coreceptors in cerebrospinal fluid (CSF) and plasma in 46 subjects...
  23. ncbi request reprint T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection
    Jutta K Neuenburg
    Department of Neurology, San Francisco General Hospital, General Clinical Research Center at the University of California, San Francisco, CA 94158, USA
    J Acquir Immune Defic Syndr 39:16-22. 2005
    ..In HIV-infection, activated CD4+ and CD8+ T cells in CSF were more abundant than in uninfected controls. As expected, combination antiretroviral therapy (ART) reduced T cell activation in CSF and blood...
  24. ncbi request reprint HIV-producing T cells in cerebrospinal fluid
    Jutta K Neuenburg
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 37:1237-44. 2004
    ..In HIV-1 infection, CSF white cell counts seem to contain a large number of uninfected cells. White cell counts and viral load in CSF may result from systemic inflammation and immune activation...
  25. ncbi request reprint HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy
    Jutta K Neuenburg
    Department of Neurology, University of California, San Francisco, USA
    J Acquir Immune Defic Syndr 31:171-7. 2002
    ..Although combination therapies decrease overall mortality and prevalence of CNS opportunistic infections, these therapies may be less active in preventing direct HIV-1 effects on the brain...
  26. ncbi request reprint Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure
    Serena Spudich
    Department of Neurology, San Francisco General Hospital, University of California, San Francisco, CA 94110 3518, USA
    J Infect Dis 194:1686-96. 2006
    ..To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)-1 RNA levels and CSF inflammation...
  27. ncbi request reprint Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex
    F Aweeka
    Department of Clinical Pharmacy, University of California, San Francisco 94143 0622, USA
    J Acquir Immune Defic Syndr Hum Retrovirol 20:39-43. 1999
    ..To assess the penetration of the HIV-1 protease inhibitor, nelfinavir, into cerebrospinal fluid (CSF)...
  28. ncbi request reprint A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy
    Judith A Aberg
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    J Infect Dis 185:1179-82. 2002
    ..Disseminated cryptococcal disease can be cured by prolonged antifungal therapy in some patients with AIDS who experience sustained CD4 lymphocyte increases while receiving HAART...
  29. ncbi request reprint Chemokine receptors, neural progenitor cells, and the AIDS dementia complex
    Aimee W Kao
    J Infect Dis 190:211-5. 2004
  30. ncbi request reprint Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy
    Arvid Edén
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Infect Dis 196:1779-83. 2007
    ..5 years, a substantial proportion of patients continue to show signs of macrophage/microglia activation and intrathecal immunoglobulin production in the CNS...
  31. ncbi request reprint Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers
    Magnus Gisslen
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Neuroimmune Pharmacol 2:112-9. 2007
    ..Careful analysis of this and other marker combinations promises more rational trial design and more rapid progress in managing CNS HIV infection and HRND using both antiviral and adjuvant treatment approaches...
  32. pmc Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy
    Aylin Yilmaz
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Acquir Immune Defic Syndr 47:168-73. 2008
    ....
  33. ncbi request reprint The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations
    Paola Cinque
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, University of Milan, Italy
    Ann Neurol 55:687-94. 2004
    ..The overexpression of uPAR in the CNS of patients with ADC suggests that the uPA/uPAR system may contribute to the tissue injury and neuronal damage in this disease...
  34. ncbi request reprint Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients
    Lucette A Cysique
    St Vincent s Hospital Clinical School, University of New South Wales, Darlinghurst, Sydney, Australia
    J Acquir Immune Defic Syndr 39:426-9. 2005
    ....
  35. ncbi request reprint Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection
    Paola Cinque
    Clinic of Infectious Diseases, San Raffaele Hospital, Milan, Italy
    J Neuroimmunol 168:154-63. 2005
    ..High CSF levels may be useful in the diagnosis of ADC in subjects with advanced immunosuppression in whom CMV encephalitis has been ruled out, though this issue requires further study...
  36. ncbi request reprint Timed Gait test: normative data for the assessment of the AIDS dementia complex
    Kevin R Robertson
    AIDS Neurological Center and Department of Neurology, School of Medicine, University of North Carolina at Chapel Hill, NC 27599 7025, USA
    J Clin Exp Neuropsychol 28:1053-64. 2006
    ..These normative data should prove useful in both recognition of ADC and treatment response. Given its minimal training requirements, the Timed Gait would have utility in resource limited settings...
  37. ncbi request reprint CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration
    Sahra Abdulle
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Gothenburg, Sweden
    J Neurol 254:1026-32. 2007
    ..The effect of highly active antiretroviral treatment (HAART) was studied by repeated CSF sampling in four of the ADC patients initiating treatment...
  38. ncbi request reprint Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex
    Magnus Gisslen
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, SE 416 85, Sweden, and Department of Neurology, St Vincent s Hospital, Sydney, NSW, Australia
    J Infect Dis 195:1774-8. 2007
    ..By contrast, no differences were found in CSF HIV-1 RNA or neopterin concentrations between the 2 groups. CSF NFL may prove to be a useful predictive marker for ADC...
  39. ncbi request reprint Neurological complications of HIV infection and AIDS: current and future perspectives
    Paola Cinque
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Neurovirol 11:1-5. 2005
  40. ncbi request reprint Screening for the AIDS dementia complex
    Richard W Price
    AIDS Read 12:32-3. 2002
  41. ncbi request reprint Editorial comment: diagnosis of focal brain lesions--old lessons retaught
    Richard W Price
    AIDS Read 13:553. 2003
  42. ncbi request reprint Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease
    Nicolai Sidenius
    Molecular Genetics Unit, DIBIT, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
    J Neuroimmunol 157:133-9. 2004
    ..Additionally, these findings are consistent with a model in which overexpression of uPAR and overproduction of its soluble form may promote HIV replication via binding and removal of uPA from cell surface...
  43. ncbi request reprint Editorial comment: déjà vu--neurologic complications of HIV infection in the expanding epidemic
    Richard W Price
    AIDS Read 15:144. 2005
  44. ncbi request reprint Editorial comment: AIDS dementia complex in the current era
    Richard W Price
    AIDS Read 16:630-1. 2006
  45. pmc Determination of the underlying cause of death in three multicenter international HIV clinical trials
    Alan R Lifson
    University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
    HIV Clin Trials 9:177-85. 2008
    ..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials...

Research Grants24

  1. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2004
    ..abstract_text> ..
  2. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2004
    ....
  3. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2004
    ....
  4. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2005
    ..abstract_text> ..
  5. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2006
    ..abstract_text> ..
  6. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2006
    ..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
  7. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2007
    ..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
  8. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2009
    ..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
  9. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2003
    ....
  10. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2003
    ....
  11. CFS FLUID AFTER RETROVIRAL TREATMENT FOR HIV
    Richard Price; Fiscal Year: 1999
    ..Antiviral effects will be correlated with the kinetics of drug entry into the CSF. ..
  12. CFS FLUID AFTER RETROVIRAL TREATMENT FOR HIV
    Richard Price; Fiscal Year: 2000
    ..Antiviral effects will be correlated with the kinetics of drug entry into the CSF. ..
  13. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2001
    ....
  14. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2001
    ....
  15. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2002
    ..abstract_text> ..
  16. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2001
    ....
  17. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2002
    ....
  18. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2002
    ....
  19. CSF Molecular Marker Study Consortium
    Richard Price; Fiscal Year: 2003
    ..abstract_text> ..
  20. CSF & Lymphocyte Dynamics in HIV Infection
    Richard W Price; Fiscal Year: 2010
    ..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..